No Data
No Data
No Data
No Data
No Data
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen (OCGN) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration.
MT NewswiresApr 19 08:19 ET
Express News | Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 Armada Clinical Trial of Ocu410—a Modifier Gene Therapy
Moomoo 24/7Apr 19 07:13 ET
Ocugen Announces Dosing Completion of Subjects With Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene a
OcugenApr 19 00:00 ET
Ocugen Stock Jumps After $175M Securities Filing
Seeking AlphaApr 18 06:21 ET
Express News | Ocugen Inc Files for Mixed Shelf of up to $175 Mln - SEC Filing
Moomoo 24/7Apr 18 06:02 ET
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...
Stockhouse Apr 14 11:00 ET
No Data
No Data